<?xml version="1.0" encoding="UTF-8"?>
<p id="Par88">Numerous cathepsin inhibitors have been prepared in the past. However, despite a few proof of concept studies, their deeper characterization and optimization as antivirals are limited, so far. They have been mainly tested in nonviral applications, e.g., for cancer therapy, osteoporosis, and rheumatoid arthritis or in neurodegenerative diseases (Siklos et al. 
 <xref ref-type="bibr" rid="CR173">2015</xref>; Turk et al. 
 <xref ref-type="bibr" rid="CR192">2012</xref>).
</p>
